{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:36:53Z","timestamp":1783579013780,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,21]]},"DOI":"10.7759\/cureus.82722","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T17:43:16Z","timestamp":1745257396000},"source":"Crossref","is-referenced-by-count":3,"title":["Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives"],"prefix":"10.7759","author":[{"given":"Mahmoud M","family":"Ramadan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad A","family":"Al-Najjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokia S","family":"Abady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala A","family":"Obaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen A","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad T","family":"Al-Obeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Elmahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02136-y","article-title":"Advances in clinical cardiology 2021: a summary of key clinical trials","volume":"39","author":"Savage P","year":"2022","unstructured":"Savage P, Cox B, Linden K, Coburn J, Shahmohammadi M, Menown I. Advances in clinical cardiology 2021: a summary of key clinical trials. Adv Ther. 2022, 39:2398-437. 10.1007\/s12325-022-02136-y","journal-title":"Adv Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.033767","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy: rationale for clinically guided dose titration to optimize individual response","volume":"13","author":"Owens AT","year":"2024","unstructured":"Owens AT, Desai M, Wheeler MT, Rodonski A, Merali S, Sehnert AJ, Saberi S. Mavacamten for obstructive hypertrophic cardiomyopathy: rationale for clinically guided dose titration to optimize individual response. J Am Heart Assoc. 2024, 13:e033767. 10.1161\/JAHA.124.033767","journal-title":"J Am Heart Assoc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.07.007","article-title":"Comparison of drug therapy efficacy in patients with hypertrophic cardiomyopathy: a network meta-analysis","volume":"226","author":"Shang E","year":"2024","unstructured":"Shang E, Tan H. Comparison of drug therapy efficacy in patients with hypertrophic cardiomyopathy: a network meta-analysis. Am J Cardiol. 2024, 226:97-107. 10.1016\/j.amjcard.2024.07.007","journal-title":"Am J Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.02.007","article-title":"Mavacamten: a novel agent for hypertrophic cardiomyopathy","volume":"46","author":"Chase Cole J","year":"2024","unstructured":"Chase Cole J, Benvie SF, DeLosSantos M. Mavacamten: a novel agent for hypertrophic cardiomyopathy. Clin Ther. 2024, 46:368-73. 10.1016\/j.clinthera.2024.02.007","journal-title":"Clin Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho CY","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG, et al.. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020, 75:2649-60. 10.1016\/j.jacc.2020.03.064","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59497","article-title":"Racial and socioeconomic determinants of cardiovascular health: a comprehensive review","volume":"16","author":"Borkowski P","year":"2024","unstructured":"Borkowski P, Borkowska N, Mangeshkar S, Adal BH, Singh N. Racial and socioeconomic determinants of cardiovascular health: a comprehensive review. Cureus. 2024, 16:e59497. 10.7759\/cureus.59497","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald E","year":"2023","unstructured":"Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J. 2023, 44:4622-33. 10.1093\/eurheartj\/ehad637","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo MP","year":"2019","unstructured":"Grillo MP, Erve JC, Dick R, et al.. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica. 2019, 49:718-33. 10.1080\/00498254.2018.1495856","journal-title":"Xenobiotica"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1720342115","article-title":"Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin","volume":"115","author":"Rohde JA","year":"2018","unstructured":"Rohde JA, Roopnarine O, Thomas DD, Muretta JM. Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proc Natl Acad Sci U S A. 2018, 115:E7486-94. 10.1073\/pnas.1720342115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo7622","article-title":"Mavacamten, a precision medicine for hypertrophic cardiomyopathy: from a motor protein to patients","volume":"9","author":"Nag S","year":"2023","unstructured":"Nag S, Gollapudi SK, Del Rio CL, Spudich JA, McDowell R. Mavacamten, a precision medicine for hypertrophic cardiomyopathy: from a motor protein to patients. Sci Adv. 2023, 9:eabo7622. 10.1126\/sciadv.abo7622","journal-title":"Sci Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12551-021-00840-7","article-title":"Cardiac sarcomere mechanics in health and disease","volume":"13","author":"Crocini C","year":"2021","unstructured":"Crocini C, Gotthardt M. Cardiac sarcomere mechanics in health and disease. Biophys Rev. 2021, 13:637-52. 10.1007\/s12551-021-00840-7","journal-title":"Biophys Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2016.00562","article-title":"Myofilament calcium sensitivity: role in regulation of in vivo cardiac contraction and relaxation","volume":"7","author":"Chung JH","year":"2016","unstructured":"Chung JH, Biesiadecki BJ, Ziolo MT, Davis JP, Janssen PM. Myofilament calcium sensitivity: role in regulation of in vivo cardiac contraction and relaxation. Front Physiol. 2016, 7:562. 10.3389\/fphys.2016.00562","journal-title":"Front Physiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082234","article-title":"Cardiomyopathies and related changes in contractility of human heart muscle","volume":"19","author":"Vikhorev PG","year":"2018","unstructured":"Vikhorev PG, Vikhoreva NN. Cardiomyopathies and related changes in contractility of human heart muscle. Int J Mol Sci. 2018, 19:2234. 10.3390\/ijms19082234","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2023.02.005","article-title":"Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients","volume":"44","author":"Zatorski N","year":"2023","unstructured":"Zatorski N, Sobie EA, Schlessinger A. Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients. Trends Pharmacol Sci. 2023, 44:318-9. 10.1016\/j.tips.2023.02.005","journal-title":"Trends Pharmacol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15271","article-title":"Effects of mavacamten on Ca2+ sensitivity of contraction as sarcomere length varied in human myocardium","volume":"177","author":"Awinda PO","year":"2020","unstructured":"Awinda PO, Bishaw Y, Watanabe M, Guglin MA, Campbell KS, Tanner BC. Effects of mavacamten on Ca2+ sensitivity of contraction as sarcomere length varied in human myocardium. Br J Pharmacol. 2020, 177:5609-21. 10.1111\/bph.15271","journal-title":"Br J Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00345.2020","article-title":"Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy","volume":"320","author":"Awinda PO","year":"2021","unstructured":"Awinda PO, Watanabe M, Bishaw Y, et al.. Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2021, 320:H881-90. 10.1152\/ajpheart.00345.2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009627","article-title":"Impact of the myosin modulator mavacamten on force generation and cross-bridge behavior in a murine model of hypercontractility","volume":"7","author":"Mamidi R","year":"2018","unstructured":"Mamidi R, Li J, Doh CY, Verma S, Stelzer JE. Impact of the myosin modulator mavacamten on force generation and cross-bridge behavior in a murine model of hypercontractility. J Am Heart Assoc. 2018, 7:e009627. 10.1161\/JAHA.118.009627","journal-title":"J Am Heart Assoc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-021-00523-0","article-title":"Pathophysiology and treatment of hypertrophic cardiomyopathy: new perspectives","volume":"18","author":"Zampieri M","year":"2021","unstructured":"Zampieri M, Berteotti M, Ferrantini C, et al.. Pathophysiology and treatment of hypertrophic cardiomyopathy: new perspectives. Curr Heart Fail Rep. 2021, 18:169-79. 10.1007\/s11897-021-00523-0","journal-title":"Curr Heart Fail Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01739-7","article-title":"Mavacamten: first approval","volume":"82","author":"Keam SJ","year":"2022","unstructured":"Keam SJ. Mavacamten: first approval. Drugs. 2022, 82:1127-35. 10.1007\/s40265-022-01739-7","journal-title":"Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.5099","article-title":"Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial","volume":"8","author":"Wheeler MT","year":"2023","unstructured":"Wheeler MT, Olivotto I, Elliott PM, et al.. Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial. JAMA Cardiol. 2023, 8:240-7. 10.1001\/jamacardio.2022.5099","journal-title":"JAMA Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.17925\/HI.2023.17.1.2","article-title":"Mavacamten, an alternative to septal reduction therapy for patients with hypertrophic cardiomyopathy","volume":"17","author":"Desai MY","year":"2023","unstructured":"Desai MY, Hajj Ali A. Mavacamten, an alternative to septal reduction therapy for patients with hypertrophic cardiomyopathy. Heart Int. 2023, 17:2-4. 10.17925\/HI.2023.17.1.2","journal-title":"Heart Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia P","year":"2024","unstructured":"Garcia-Pavia P, Or\u0119ziak A, Masri A, et al.. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024, 45:5071-83. 10.1093\/eurheartj\/ehae579","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto I","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al.. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020, 396:759-69. 10.1016\/S0140-6736(20)31792-X","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner SB","year":"2019","unstructured":"Heitner SB, Jacoby D, Lester SJ, et al.. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019, 170:741-8. 10.7326\/M18-3016","journal-title":"Ann Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.3810","article-title":"Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction: primary results of the EMBARK-HFpEF trial","volume":"10","author":"Shah SJ","year":"2025","unstructured":"Shah SJ, Rigolli M, Javidialsaadi A, et al.. Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction: primary results of the EMBARK-HFpEF trial. JAMA Cardiol. 2025, 10:170-5. 10.1001\/jamacardio.2024.3810","journal-title":"JAMA Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441","article-title":"Mavacamten: real-world experience from 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program","volume":"18","author":"Desai MY","year":"2025","unstructured":"Desai MY, Seto D, Cheung M, et al.. Mavacamten: real-world experience from 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program. Circ Heart Fail. 2025, 18:e012441. 10.1161\/CIRCHEARTFAILURE.124.012441","journal-title":"Circ Heart Fail"},{"key":"ref27","unstructured":"U.S. Food and Drug Administration approves Camzyos\u2122 (mavacamten) for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. (2022). https.\/\/news.bms.com\/news\/details\/2022\/U.S.-Food-and-Drug-Administration-Approves-Camzyos-mavacamten-for-the-Treatmen...."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai MY","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, et al.. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol. 2023, 8:968-77. 10.1001\/jamacardio.2023.3342","journal-title":"JAMA Cardiol"},{"key":"ref29","unstructured":"ODYSSEY-HCM. a randomized, double-blind, placebo-controlled clinical study to evaluate mavacamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathy - 2022-77. (2025). https:\/\/clinicalresearch.pennmedicine.org\/us\/en\/listing\/7705\/odyssey-hcm-a-randomized-double-blind\/.."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030607","article-title":"Long-term safety and efficacy of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy: interim results of the PIONEER-OLE study","volume":"13","author":"Masri A","year":"2024","unstructured":"Masri A, Lester SJ, Stendahl JC, et al.. Long-term safety and efficacy of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy: interim results of the PIONEER-OLE study. J Am Heart Assoc. 2024, 13:e030607. 10.1161\/JAHA.123.030607","journal-title":"J Am Heart Assoc"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction","volume":"10","author":"Oktay AA","year":"2013","unstructured":"Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013, 10:401-10. 10.1007\/s11897-013-0155-7","journal-title":"Curr Heart Fail Rep"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer MA","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, et al.. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015, 131:34-42. 10.1161\/CIRCULATIONAHA.114.013255","journal-title":"Circulation"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan M","year":"2023","unstructured":"Vaduganathan M, Mentz RJ, Claggett BL, et al.. Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023, 44:2982-93. 10.1093\/eurheartj\/ehad344","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13393","article-title":"Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved","volume":"15","author":"Coats AJ","year":"2024","unstructured":"Coats AJ, Butler J, Tsutsui H, et al.. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved. J Cachexia Sarcopenia Muscle. 2024, 15:412-24. 10.1002\/jcsm.13393","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref35","unstructured":"A long-term safety extension study of mavacamten in adults who have completed MAVERICK-HCM or EXPLORER-HCM. (2024). https.\/\/clinicaltrials.gov\/study\/NCT03723655."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo E","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al.. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023, 44:3503-626. 10.1093\/eurheartj\/ehad194","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.05.003","article-title":"Doing our part to get with the heart failure guidelines","volume":"11","author":"Joynt Maddox KE","year":"2023","unstructured":"Joynt Maddox KE, Fox DK. Doing our part to get with the heart failure guidelines. JACC Heart Fail. 2023, 11:930-2. 10.1016\/j.jchf.2023.05.003","journal-title":"JACC Heart Fail"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2024.102430","article-title":"Usefulness of mavacamten in the challenging association of aortic stenosis and obstructive hypertrophic cardiomyopathy","volume":"29","author":"Vanhaecke P","year":"2024","unstructured":"Vanhaecke P, Bohbot Y, Di Lena C, Hucleux E, Yemmi M, Tribouilloy C. Usefulness of mavacamten in the challenging association of aortic stenosis and obstructive hypertrophic cardiomyopathy. JACC Case Rep. 2024, 29:102430. 10.1016\/j.jaccas.2024.102430","journal-title":"JACC Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/354021-mavacamten-cardiac-myosin-inhibitor-clinical-applications-and-future-perspectives","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T17:43:18Z","timestamp":1745257398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/354021-mavacamten-cardiac-myosin-inhibitor-clinical-applications-and-future-perspectives"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.82722","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}